Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

China Medical Technologies Reports First Fiscal Quarter Financial Results


News provided by

China Medical Technologies, Inc.

Aug 16, 2011, 05:49 ET

Share this article

Share toX

Share this article

Share toX

BEIJING, Aug. 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, announced its unaudited financial results for the first fiscal quarter ended June 30, 2011 ("1Q FY2011") today.

1Q FY2011 Highlights





For the Three Months Ended




June 30, 2010


June 30, 2011


June 30, 2011




RMB


RMB


US$


% change


(in thousands except for per ADS information)



Net revenues

186,170


237,111


36,685


27.4%

Net income

33,678


35,728


5,528


6.1%

Diluted earnings per ADS*

1.29


1.35


0.21


4.7%

Non-GAAP net income

57,011


90,452


13,995


58.7%

Non-GAAP diluted earnings per ADS*          

2.18


3.42


0.53


56.9%

Adjusted EBITDA

105,152


154,289


23,871


46.7%



For the Three Months Ended




March 31, 2011


June 30, 2011


June 30, 2011




RMB


RMB


US$


% change


(in thousands)



Net cash provided by operating activities                  

37,339


62,243


9,630


66.7%



As of




March 31, 2011


June 30, 2011


June 30, 2011




RMB


RMB


US$


% change


(in thousands)



Cash and cash equivalents

1,123,818


1,239,458


191,763


10.3%

Trade accounts receivable, net                

481,096


565,061


87,422


17.5%

Convertible notes

2,752,304


2,669,914


413,076


(3.0)%

Outlook for second fiscal quarter ending September 30, 2011





For the Three Months Ending September 30, 2011


Year over Year


RMB


US$


% change


(in millions except for per ADS information)



Target net revenues

238.0 – 240.0


36.8 – 37.1


17.9 – 18.9%

Target non-GAAP net income

82.0 –  84.0


12.7 – 13.0


25.4 – 28.4%

Target non-GAAP diluted earnings per ADS*          

3.07 –  3.15


0.47 – 0.49


22.8 – 26.0%



Outlook for the full fiscal year ending March 31, 2012





For the Fiscal Year Ending March 31, 2012


Year over Year


RMB


US$


% change


(in millions except for per ADS information)



Target net revenues

970.0 – 995.0


150.1 – 153.9


15.2 – 18.1%

Target non-GAAP net income

315.0 – 325.0


48.7 –  50.3


15.4 – 19.0%

Target non-GAAP diluted earnings per ADS*          

11.75 – 12.13


1.82 –  1.88


13.1 – 16.7%

The above targets are based on the Company's current views on operating and market conditions, which are subject to change.

*One American Depositary Share ("ADS") = 10 ordinary shares

See "Non-GAAP Measure Disclosures" below, where the impact of certain items on reported results is discussed.

"We have recently implemented the first steps of two new initiatives which will support our long term growth," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We have established a collaboration with Da An Health for our domestic market as well as a collaboration with Leica Microsystems for both the domestic and the international markets. Da An Health is a fast growing independent laboratory service network serving mainly small and mid-size hospitals in China. We believe this collaboration will help us penetrate over time a new and big customer group for our molecular diagnostic products in a cost effective way. The collaboration with Leica Microsystems is to implement our strategy to enter the international market for our products through partnerships with leading global players. The partnership with Leica Microsystems substantially reduces our business risks and costs associated with entering the international market considering the complicated regulatory approval processes, medical reimbursement conditions and distribution channels in different countries and regions. The joint research and development with Leica Microsystems to automate our FISH probes on Leica's BOND system is important for the high volume users such as independent laboratory service networks in major global markets as well as existing and potential high volume hospital users in China. We are working closely with our new partners to realize the value of these collaborations for all of us. Meanwhile, we are also in discussion with a number of leading global players for different types of collaborations for our other molecular diagnostic products."

"Our DSO increased in recent quarters due to slower payment from some of our ECLIA distributors and the change in our sales mix," commented Mr. Sam Tsang, Chief Financial Officer of the Company. "ECLIA distributors normally pay in about 3 months but some of them took longer time to pay in the past few quarters. Slower payments from distributors indicate a possible risk of bad debt, and we have recently taken measures to control this risk including lowering credit limit for certain slow paying distributors and control over the order fulfillment for these distributors according to their payments. Meanwhile, we are adding new distributors to diversify the risk. The change in sales mix relates to the increasing portion of our revenues from our molecular diagnostic products which we sell to hospitals directly. These hospitals normally pay us in 6 to 12 months and the bigger the hospital, the longer the payment cycle. However, we consider the risk of bad debt from these hospitals to be very low considering that they are tier 1 hospitals, have a strong financial position and are government-owned. Recently, we have increased compensation of our direct sales personnel based on collection from hospitals to increase incentive for collection. On the other hand, despite the increase in DSO in the past few quarters, we still generated sizeable cash flows from operations. We expect our DSO to become stable and decline in the coming quarters."

"We are confident in handling our convertible debts before maturity," further commented Mr. Sam Tsang. "The nearest maturity of convertible debts is approximately US$17 million in November this year which is a small amount considering our cash position of approximately US$192 million. The next maturity of approximately US$247 million of convertible debts will be in August 2013. We believe that our current cash position, our future free cash flows and our access to other sources of funds such as commercial banks in China will provide sufficient liquidity to pay off the debts before maturity. We have noticed that the debts have been trading at a substantial discount which is favorable to us."

1Q FY2011 Unaudited Financial Results

The Company reported net revenues of RMB237.1 million (US$36.7 million) for 1Q FY2011, representing a 27.4% increase from the corresponding period of FY2010.

The Company's revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The molecular diagnostic system segment mainly includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products.

Molecular diagnostic system sales for 1Q FY2011 were RMB156.1 million (US$24.2 million), representing a 44.5% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in usage of the Company's FISH probes by hospitals as well as the significant increase in sales of SPR-based HPV-DNA chips to hospitals during 1Q FY2011.

Immunodiagnostic system sales for 1Q FY2011 were RMB81.0 million (US$12.5 million), representing a 3.7% increase from the corresponding period of FY2010.

Gross margin was 62.9% for 1Q FY2011 which decreased year-over-year from 67.0% for the corresponding period of FY2010. The year-over-year decrease was primarily due to the reclassification of amortization of SPR intangible assets from operating expenses to cost of revenues after the commencement of sales of HPV-DNA chips in 2Q FY2010. Such factor was partially offset by the positive impact of more contribution from the sales of FISH probes and HPV-DNA chips which generate higher gross margin and a decrease in the number of free ECLIA analyzers provided to distributors and free SPR analyzers provided to hospitals. Non-GAAP gross margin was 83.1% for 1Q FY2011 which increased year-over-year from 79.1% for the corresponding period of FY2010. The year-over-year increase in non-GAAP gross margin was primarily due to more contribution from the sales of FISH probes and HPV-DNA chips and the decrease in free ECLIA analyzers and SPR analyzers as noted above.

Research and development expenses were RMB10.8 million (US$1.7 million) for 1Q FY2011, representing a 1.1% year-over-year increase. The year-over-year increase was primarily due to an increase in salaries of research personnel offset by a decrease in stock compensation expense. Non-GAAP research and development expenses were RMB9.7 million (US$1.5 million) for 1Q FY2011, representing a 5.3% year-over-year increase. The year-over-year increase was primarily due to the increase in salaries of research personnel.

Sales and marketing expenses were RMB23.3 million (US$3.6 million) for 1Q FY2011, representing a 27.4% year-over-year increase. Non-GAAP sales and marketing expenses were RMB23.0 million (US$3.6 million) for 1Q FY2011, representing a 26.5% year-over-year increase. The year-over-year increases were primarily due to an increase in direct sales efforts for molecular diagnostic systems.

General and administrative expenses were RMB22.6 million (US$3.5 million) for 1Q FY2011, representing a 10.1% year-over-year decrease. The year-over-year decrease was primarily due to a decrease in stock compensation expense. Non-GAAP general and administrative expenses were RMB16.3 million (US$2.5 million) for 1Q FY2011, representing a 1.4% year-over-year increase.

Interest expense on convertible notes was RMB33.3 million (US$5.2 million) for 1Q FY2011. Non-GAAP interest expense on convertible notes was RMB32.4 million (US$5.0 million) for 1Q FY2011. As of June 30, 2011, the Company's outstanding convertible notes of US$16.7 million, US$246.5 million and US$150.0 million in principal value bear interest at 3.5%, 4% and 6.25% per annum, respectively, and will mature in November 2011, August 2013 and December 2016, respectively.

Interest expense related to amortization of convertible notes issuance costs was RMB4.0 million (US$0.6 million) for 1Q FY2011.

Interest expense related to amortization of share lending costs was RMB2.3 million (US$0.4 million) for 1Q FY2011.

Other income was RMB4.8 million (US$0.7 million) for 1Q FY2011, representing a 88.9% year-over-year decrease. The significant year-over-year decrease was primarily due to a decrease in gain on repurchase of convertible notes.

Income tax expense was RMB29.3 million (US$4.5 million) for 1Q FY2011. The high effective tax rate was due to the fact that certain expenses of the Company such as stock compensation expense, amortization of acquired intangible assets and interest expense of convertible notes were not deductible for income tax purpose. In addition, the Company was required to accrue for withholding income tax on distributable earnings generated in China which the Company does not intend to permanently reinvest in China.

Net income was RMB35.7 million (US$5.5 million) for 1Q FY2011, representing a 6.1% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales offset by the decrease in gain on repurchase of convertible notes. Non-GAAP net income was RMB90.5 million (US$14.0 million) for 1Q FY2011, representing a 58.7% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales and other reasons mentioned above.

Earnings before interest, taxes, depreciation and amortization ("EBITDA") was RMB150.6 million (US$23.3 million) for 1Q FY2011, representing a 6.1% increase from the corresponding period of FY2010. The year-over-year increase was primarily due to the increase in molecular diagnostic system sales offset by the decrease in gain on repurchase of convertible notes.

Adjusted EBITDA was RMB154.3 million (US$23.9 million) for 1Q FY2011, representing a 46.7% increase from the corresponding period of FY2010. The increase was primarily due to increased sales in 1Q FY2011.

Stock compensation expense for 1Q FY2011 was RMB7.8 million (US$1.2 million), of which RMB0.2 million was allocated to cost of revenues, RMB1.0 million to research and development expenses, RMB0.3 million to sales and marketing expenses and RMB6.3 million to general and administrative expenses.

Amortization of acquired intangible assets for 1Q FY2011 was RMB47.7 million (US$7.4 million) which was all allocated to cost of revenues.

As of June 30, 2011, the Company's cash and cash equivalents were RMB1,239.5 million (US$191.8 million). Net cash generated from operating activities for 1Q FY2011 was RMB62.2 million (US$9.6 million). Net cash generated from investing activities for 1Q FY2011 was RMB96.7 million (US$15.0 million). Net cash used in financing activities for 1Q FY2011 was RMB41.6 million (US$6.4 million).

As of June 30, 2011, the Company's net accounts receivable was RMB565.1 million (US$87.4 million), representing an increase of 17.5% from the balance at March 31, 2011. The increase in net accounts receivable was primarily due to the increase in molecular diagnostic system sales to hospital customers which normally pay in 6 to 12 months and the slower payments from certain distributors of immunodiagnostic systems.

The Company evaluates the collectability of its accounts receivable based on the aging of account balances, collection history, credit quality of the customer and current economic conditions that may affect a customer's ability to pay. The Company has recognized an allowance for doubtful accounts in its consolidated financial statements. The allowance for doubtful accounts increased by RMB2.4 million (US$0.4 million) to RMB28.8 million (US$4.4 million) as of June 30, 2011 from RMB26.4 million as of March 31, 2011.

For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.4635 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, June 30, 2011. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on June 30, 2011 or at any other dates.

Non-GAAP Measure Disclosures

The Company reported its operating results in accordance with U.S. generally accepted accounting principles ("GAAP") for the three months ended June 30, 2010 and 2011. The Company also presented non-GAAP information, which included EBITDA and adjusted EBITDA, for the three months ended June 30, 2010 and 2011. The non-GAAP measures are defined below:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, excluding the effects of stock compensation expense and amortization of acquired intangible assets.
  • Non-GAAP gross margin represents non-GAAP gross profit divided by net revenues.
  • Non-GAAP research and development expenses represent research and development expenses reported in accordance with GAAP, excluding the effects of stock compensation expense.
  • Non-GAAP sales and marketing expenses represent sales and marketing expenses reported in accordance with GAAP, excluding the effects of stock compensation expense.
  • Non-GAAP general and administrative expenses represent general and administrative expenses reported in accordance with GAAP, excluding the effects of stock compensation expense.
  • Non-GAAP operating income represents operating income reported in accordance with GAAP, excluding the effects of stock compensation expense and amortization of acquired intangible assets.
  • Non-GAAP interest expense on convertible notes represents interest expense on convertible notes reported in accordance with GAAP, excluding the effects of non-cash interest expense of convertible notes.
  • Non-GAAP interest expense on amortization of share lending costs represents the exclusion of interest expense on amortization of share lending costs reported in accordance with GAAP, as this item is non-cash.
  • Non-GAAP other income (expense), net represents other income and expense, net reported in accordance with GAAP, excluding the effects of gain on repurchase of convertible notes.
  • Non-GAAP net income represents net income reported in accordance with GAAP, excluding the effects of stock compensation expense, amortization of acquired intangible assets, non-cash interest expense of convertible notes, interest expense for amortization of share lending costs as well as gain on repurchase of convertible notes.
  • Non-GAAP earnings per ADS represents non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted earnings per ADS in accordance with GAAP.
  • EBIT represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense and income tax expense.
  • EBITDA represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense, income tax expense, depreciation and amortization.
  • Adjusted EBITDA represents EBITDA excluding the effects of stock compensation expense as well as gain on repurchase of convertible notes.

Non-GAAP financial measures are used by the Company in its financial and operating decision-making because management believes they reflect the Company's ongoing business in a manner that allows meaningful period-to-period comparison. The Company's management believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company's current operating performance and future prospects in the same manner as management does, if they so choose.

The presentation of this additional financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the financial information included with this earnings announcement.

Conference Call

The Company's senior management team will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on August 16, 2011 (or 8:00 p.m. Beijing/Hong Kong time on the same date) to discuss the results following this earnings announcement.

The dial-in details for the live conference call are as follows:

-- U.S. Toll Free Number 1-866-783-2141
-- International Dial-in Number 1-857-350-1600

Passcode: CMEDCALL

A live webcast of the conference call will be available on http://ir.chinameditech.com.

A replay of this webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. U.S. Eastern Time on August 17, 2011.  

The dial-in details for the replay are as follows:

-- U.S. Toll Free Number 1-888-286-8010
-- International Dial-in Number 1-617-801-6888

Passcode: 67816623

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales personnel and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release, as well as its outlook for the second fiscal quarter ending September 30, 2011 and full fiscal year ending March 31, 2012, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contacts


Sam Tsang and Winnie Yam

Tel: +852-2511-9808

Email: [email protected]

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Balance Sheets



As of


March 31, 2011


June 30, 2011


RMB


RMB


US$


(in thousands)

Assets






Current assets






Cash and cash equivalents

1,123,818


1,239,458


191,763

Trade accounts receivable, net (1)                          

481,096


565,061


87,422

Inventories

19,273


20,315


3,143

Prepayments and other receivables

18,952


12,833


1,986

Due from a related party

98,225


-


-

        Total current assets

1,741,364


1,837,667


284,314







Property, plant and equipment, net

139,448


134,562


20,819

Land use rights

6,859


6,811


1,054

Goodwill

8,654


8,654


1,339

Intangible assets, net 

2,973,358


2,891,353


447,335

Convertible notes issuance costs

55,817


51,148


7,913

Share lending costs

22,562


19,804


3,064

        Total assets

4,948,062


4,949,999


765,838







Liabilities 






Current liabilities






Trade accounts payable

44,502


51,575


7,979

Accrued liabilities and other payables 

191,120


206,260


31,912

Convertible notes

146,081


107,136


16,576

Income taxes payable

77,954


91,939


14,224

        Total current liabilities

459,657


456,910


70,691







Convertible notes

2,606,223


2,562,778


396,500

Deferred income taxes

91,596


98,985


15,314

        Total liabilities

3,157,476


3,118,673


482,505







Shareholders' equity






Ordinary shares US$0.1 par value:






    500,000,000 authorized; 322,680,001 issued and 
    outstanding as of March 31, 2011 and June 30, 2011

258,840


258,840


40,046

Additional paid-in capital

875,448


881,287


136,348

Treasury stock

(201,362)


(201,362)


(31,154)

Accumulated other comprehensive loss

(77,293)


(78,120)


(12,086)

Retained earnings

934,953


970,681


150,179

        Total shareholders' equity

1,790,586


1,831,326


283,333

        Total liabilities and shareholders' equity 

4,948,062


4,949,999


765,838


Note:







As of


March 31, 2011


June 30, 2011


RMB'000


RMB'000


US$'000

(1)      Trade accounts receivable

507,482


593,814


91,871

Allowance for doubtful accounts

(26,386)


(28,753)


(4,449)

Trade accounts receivable, net        

481,096


565,061


87,422

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Statements of Income and

Reconciliations of GAAP Measures to Non-GAAP Measures



For the Three Months Ended


For the Three Months Ended


June 30, 2010


June 30, 2011


GAAP


Adjustments


Non-GAAP


GAAP


Adjustments


Non-GAAP


RMB


RMB


RMB


RMB


RMB


RMB


(in thousands except for per ADS information)













Net revenues (1)

186,170


-


186,170


237,111


-


237,111

Cost of revenues (2)

(61,354)


22,466


(38,888)


(87,880)


47,920


(39,960)

Gross profit

124,816


22,466


147,282


149,231


47,920


197,151

Operating expenses 












     Research and 
       development (3)

(10,632)


1,418


(9,214)


(10,752)


1,048


(9,704)

     Sales and marketing (3)

(18,266)


91


(18,175)


(23,263)


265


(22,998)

     General and 
       administrative (3)

(25,149)


9,031


(16,118)


(22,613)


6,270


(16,343)

     Amortization of 
       SPR intangible 
       assets (4)

(27,329)


27,329


-


-


-


-

Total operating expenses

(81,376)


37,869


(43,507)


(56,628)


7,583


(49,045)

Operating income

43,440


60,335


103,775


92,603


55,503


148,106

     Interest income

4,597


-


4,597


7,336


-


7,336

     Interest expense – 
       convertible notes (5)

(32,505)


7,916


(24,589)


(33,347)


990


(32,357)

     Interest expense – 
       amortization of convertible
       notes issuance costs

(4,012)


-


(4,012)


(4,007)


-


(4,007)

     Interest expense – 
       amortization of
       share lending costs (6)

(2,475)


2,475


-


(2,343)


2,343


-

     Other income (expense), 
       net (7)

43,295


(47,393)


(4,098)


4,794


(4,112)


682

Income before 
      income tax

52,340


23,333


75,673


65,036


54,724


119,760

Income tax expense

(18,662)


-


(18,662)


(29,308)


-


(29,308)

Net income

33,678


23,333


57,011


35,728


54,724


90,452

Earnings per ADS












- basic (8)

1.30


0.89


2.19


1.36


2.08


3.44

- diluted (8)

1.29


0.89


2.18


1.35


2.07


3.42

Weighted average number of ADS












- basic (8)

26,005,975


-


26,005,975


26,300,264


-


26,300,264

- diluted (8)

26,128,403


-


26,128,403


26,485,024


-


26,485,024

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Statements of Income and

Reconciliations of GAAP Measures to Non-GAAP Measures

Convenience Translation for Reference Only



For the Three Months Ended


June 30, 2011


GAAP


Adjustments


Non-GAAP


US$


US$


US$


(in thousands except for per ADS information)







Net revenues (1)

36,685


-


36,685

Cost of revenues (2)

(13,597)


7,414


(6,183)

Gross profit

23,088


7,414


30,502

Operating expenses                             






   Research and development (3)

(1,664)


163


(1,501)

   Sales and marketing (3)

(3,599)


41


(3,558)

   General and administrative (3)

(3,498)


970


(2,528)

    Amortization of SPR intangible assets (4)

-


-


-

     Total operating expenses

(8,761)


1,174


(7,587)

Operating income

14,327


8,588


22,915

   Interest income

1,135


-


1,135

   Interest expense – convertible notes (5)

(5,159)


153


(5,006)

   Interest expense – amortization of 
     convertible notes issuance costs

(620)


-


(620)

   Interest expense – amortization of 
     share lending costs (6)

(363)


363


-

   Other income (expense), net (7)

742


(637)


105

Income before income tax

10,062


8,467


18,529

Income tax expense

(4,534)


-


(4,534)

Net income

5,528


8,467


13,995

Earnings per ADS






- basic (8)

0.21


0.32


0.53

- diluted (8)

0.21


0.32


0.53

Weighted average number of ADS






- basic (8)

26,300,264


-


26,300,264

- diluted (8)

26,485,024


-


26,485,024


For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.4635 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, June 30, 2011. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on June 30, 2011 or at any other dates.


Notes:



For the Three Months Ended


June 30, 2010


June 30, 2011

(1)   Net revenues

RMB'000


RMB'000


US$'000

- Molecular diagnostic systems

108,092


156,144


24,158

- Immunodiagnostic systems

78,078


80,967


12,527


186,170


237,111


36,685

Molecular diagnostic systems






 - HPV-DNA chips                                        

18


14,050


2,174


(2) Non-GAAP numbers exclude stock compensation expense and amortization of acquired intangible assets.



For the Three Months Ended


June 30, 2010


June 30, 2011


RMB'000


RMB'000


US$'000







Stock compensation expense

52


243


38

Amortization of acquired intangible assets              

22,414


47,677


7,376


22,466


47,920


7,414


(3)  Non-GAAP numbers exclude stock compensation expense.


(4)  Non-GAAP numbers exclude amortization of acquired intangible assets.


(5)  Non-GAAP numbers exclude non-cash interest expense of convertible notes.


(6)  Non-GAAP numbers exclude interest expense for amortization of share lending costs.


(7)  Non-GAAP numbers exclude gain on repurchase of convertible notes.



For the Three Months Ended


June 30, 2010


June 30, 2011


RMB'000


RMB'000


US$'000







 Gain on repurchase of convertible notes                    

47,393


4,112


637


(8)  Interest expense and amortization in connection with convertible notes were not added back in computing GAAP diluted earnings per ADS because they were anti-dilutive. Non-GAAP earnings per ADS represents non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted earnings per ADS in accordance with GAAP.


China Medical Technologies, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows



For the Three Months Ended


March 31, 2011


June 30, 2011


RMB


RMB


US$


(in thousands)

Cash flow from operating activities:






Net income

16,095


35,728


5,528

Adjustments to reconcile net income to net cash provided 
  by operating activities:






       Exchange loss

3,216


1,180


183

       Depreciation and amortization of property, plant 
         and equipment

5,510


5,501


851

       Amortization of intangible assets

48,185


47,677


7,376

       Non-cash interest expense on convertible notes

1,387


990


153

       Amortization of convertible notes issuance costs

4,150


4,007


620

       Amortization of share lending costs

2,386


2,343


363

       Stock compensation expense

8,519


7,826


1,212

       Land use rights expense

47


48


7

       Loss on disposal of property, plant and equipment

30


41


6

       Deferred income taxes

6,660


7,389


1,143

       Gain on repurchase of convertible notes

(1,570)


(4,112)


(637)

       Provision for allowance for doubtful accounts

6,020


2,367


366

Changes in operating assets and liabilities:






       Trade accounts receivable

(89,377)


(86,332)


(13,357)

       Prepayments and other receivables

(5,058)


1,846


286

       Inventories

(2,633)


(1,042)


(161)

       Accounts payable

25


7,073


1,094

       Accrued liabilities and other payables

19,652


15,728


2,433

       Income taxes payable

14,095


13,985


2,164

Net cash provided by operating activities

37,339


62,243


9,630







Cash flow from investing activities:






Purchase of property, plant and equipment

(737)


(656)


(102)

Purchase of intangible assets

(274)


-


-

Proceeds from sale of HIFU business

19,800


97,358


15,063

Net cash provided by investing activities

18,789


96,702


14,961







Cash flow from financing activities:






Payment for repurchase of convertible notes

(41,670)


(41,621)


(6,439)

Prepayment for repurchase of convertible notes

(4,127)


-


-

Payment for transaction cost for issuance of convertible notes

(1,647)


-


-

Payment for high yield note offering expenses

(1,477)


-


-

Net cash used in financing activities

(48,921)


(41,621)


(6,439)







Effect of foreign currency exchange rate change on cash 
  and cash equivalents

(2,773)


(1,684)


(260)

Net increase in cash and cash equivalents                          

4,434


115,640


17,892

Cash and cash equivalents at beginning of period

1,119,384


1,123,818


173,871

Cash and cash equivalents at end of period

1,123,818


1,239,458


191,763

China Medical Technologies, Inc.

EBITDA and Adjusted EBITDA Measures



For the Three Months Ended


June 30, 2010


June 30, 2011


RMB


RMB


US$


(in thousands)

Net income

33,678


35,728


5,528

Adjustments:






   Interest income

(4,597)


(7,336)


(1,135)

   Interest expense – convertible notes

32,505


33,347


5,159

   Interest expense – amortization of convertible             
     notes issuance costs

4,012


4,007


620

   Interest expense – amortization of share
     lending costs

2,475


2,343


363

   Income tax expense

18,662


29,308


4,534

EBIT (1)

86,735


97,397


15,069

Adjustments:                                                  






   Depreciation

5,475


5,501


851

   Amortization

49,743


47,677


7,376

EBITDA (2)

141,953


150,575


23,296







EBITDA (2)

141,953


150,575


23,296

Adjustments:






   Stock compensation expense

10,592


7,826


1,212

   Gain on repurchase of convertible notes

(47,393)


(4,112)


(637)

Adjusted EBITDA (3)

105,152


154,289


23,871


Notes:


(1)  EBIT represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense and income tax expense.


(2)  EBITDA represents net income reported in accordance with GAAP, excluding the effects of interest income, interest expense, income tax expense, depreciation and amortization.


(3)  Adjusted EBITDA represents EBITDA excluding the effects of stock compensation expense and gain on repurchase of convertible notes.


SOURCE China Medical Technologies, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.